ClinicalTrials.gg
RecruitingNCT04149223CCABUpdated Aug 21, 2025

Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial

An interventional study of Evidence-based standardized Cirrhosis order set in Cirrhosis, Liver, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by University of Alberta · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,975
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Liver Cirrhosis with a site in Canada — 7 open to participants now, 11 under way, 2 of them phase 3. Liver Cirrhosis · Canada.

Planned enrollment
Largest of 35
3,975 · median 151
Started
2019
with 3 others
No phase
13 of 46
1 open now
Primary completion
2026-07
later than 1 of 10 live
Registered
28th of 46
by date
Lead sponsor
4 of 46
University of Alberta

Among the 46 studies in Liver Cirrhosis with a site in Canada, this one has the largest planned enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2019, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 28th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

7 of the 46 studies in Liver Cirrhosis with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Liver Cirrhosis with a site in Canada, or all of them as a file.
02

Study summary

Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients.

The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative which will aim to improve quality of care, reduce acute care utilization and be satisfactory to both patients and providers. Best practice support will be provided in the areas of: Evidence based management of cirrhosis, alcohol use support, frailty, advance care planning, home-hospital-home transitions including standardized outpatient monitoring and structured urgent access for rapid, on-demand outpatient assessment.

Read the detailed description

Cirrhosis Care Alberta (CCAB) is a 3 year multi-component system-wide quality improvement trial which aims to improve quality of care, reduce acute care utilization and meet the needs of both patients and providers throughout Alberta. Instead of addressing just a single contributor to acute care utilization, this ambitious intervention will be the first in the world to bring together care providers across the province to tackle the complex multilevel problem with a multilevel solution. The intervention includes implementation of our standardized integrated strategy for delivering evidence-based best practices under real-world conditions to address the key determinants of hospital readmission and length of stay (LOS) in patients admitted with cirrhosis.

The CCAB project intervention includes:

  1. Comprehensive Care Bundle (development underway):

    1. Admission and Discharge/Transition order set focused on the screening and management of:

      • Cirrhosis complications
      • Frailty and malnutrition
      • Alcohol use disorder and
      • Transition to community
    2. Patient and caregiver education

      • A major theme that came up in focus group work with patients and in the literature is the lack of useful information that is available to them. This is a top priority for patients. Education will include guidelines and tools for patients to improve self-management as well as support for caregivers.
    3. Provider education

      • Nursing education focused on providing teaching to patients with cirrhosis and initiating alcohol screening and performing a brief intervention to promote abstinence is done in the minority of patients at discharge.
      • Physician education focused on cirrhosis complications and broader health needs such as prescribing pharmacological therapies for alcohol use disorder (currently done in \<5% of patients even though the number needed to treat is 12 (i.e. need to do it in 12 patients to result in a benefit)).
  2. Community Care Pathways

    1. Hepatic Encephalopathy (HE) Pathway: HE is the most common reason for admission to hospital and is a significant burden on patients and families. In collaboration with Health Link, this project aims to develop a call pathway so that patients and families can receive best practice support by nurses in the community and avoid needing to access emergency departments when HE can safely be managed in the community. The patient education surrounding HE is being developed as part of the Care Bundle, but developing a care pathway will ensure the education is translated and reinforced.
    2. Ascites Pathway: Ascites (abdominal fluid build-up) is the most common cirrhosis related complication and is extremely uncomfortable for patients. When diuretics are not tolerated or ineffective, this population typically requires frequent draining of the ascites fluid (paracentesis) to treat symptoms such as shortness of breath, pain and inability to eat. Paracentesis is usually performed in hospital based day procedure areas, but when patients can not access a scheduled paracentesis in a timely manner, they are left with no option other than going to emergency rooms. Through process mapping and identifying current barriers and facilitators with each site, the project team aims to develop effective pathways for linking patients in with timely paracentesis.
03

Conditions studied

  • Cirrhosis, Liver

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (great than 18 years of age) with a clinical diagnosis of cirrhosis (confirmed by compatible radiology, histology or fibroscan)
  • Admitted to a study hospital site

Exclusion criteria

Exclusion Criteria

o Adult patients who do not have cirrhosis

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3,975 participants (estimated)

Study arms

  • No intervention
    Control

    Current practice at baseline, routine cirrhosis care.

  • Experimental
    Intervention

    Use of a standardized cirrhosis order set.

    Other: Evidence-based standardized Cirrhosis order set

  • Active comparator
    Intervention + EMR

    Use of a standardized cirrhosis order set embedded within an electronic medical record.

    Other: Evidence-based standardized Cirrhosis order set

Interventions

  • OtherEvidence-based standardized Cirrhosis order set

    Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).

06

What researchers measure

Primary outcomes

  1. Cumulative hospital length of stay (LOS) per patient year

    LOS

    Time frame: Baseline, 1 year, 2 year

Secondary outcomes

  1. Hospital Readmission Rate

    Readmission rate

    Time frame: Baseline,through study completion, an average of 1 year

  2. Mean Length of Stay (LOS) (Ward, ICU, Total)

    LOS

    Time frame: Baseline,through study completion, an average of 1 year

  3. Readmission rate at 90 days

    Readmission rate

    Time frame: From commencement of the study (baseline), assessed quarterly until study completion.

  4. Emergency Department (ED) Visit Rate

    ED visit rate

    Time frame: Baseline,through study completion, an average of 1 year

  5. Outpatient Visit rate

    by provider type, location

    Time frame: Baseline,through study completion, an average of 1 year

  6. Survival

    Patient with cirrhosis survival

    Time frame: Baseline,through study completion, an average of 1 year

  7. Disease severity

    laboratory values, model for end-stage liver disease (MELD) score

    Time frame: Baseline,through study completion, an average of 1 year

  8. Implementation fidelity

    Adherence to cirrhosis order set

    Time frame: From commencement of the study (baseline), assessed quarterly until study completion.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Carbonneau M, Eboreime EA, Hyde A, Campbell-Scherer D, Faris P, Gramlich L, Tsuyuki RT, Congly SE, Shaheen AA, Sadler M, Zeman M, Spiers J, Abraldes JG, Sugars B, Sia W, Green L, Abdellatif D, Schaefer JP, Selvarajah V, Marr K, Ryan D, Westra Y, Bakshi N, Varghese JC, Tandon P. The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. BMC Health Serv Res. 2020 Jun 18;20(1):558. doi: 10.1186/s12913-020-05427-8. PubMed 32552833 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Jul 2026, 85 months after the start.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 85 months is above that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2019
First posted
Nov 4, 2019
StartActual
Jun 1, 2019
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jul 1, 2026
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04149223
Collaborators
Alberta Innovates Health Solutions, Alberta Health services
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Jun 1, 2019
Primary completion
Jul 1, 2026 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Aug 21, 2025

Study contacts

Puneeta Tandon, MD
Contact
ptandon@ualberta.ca
780-492-9844
Michelle Carbonneau, MN, NP
Contact
michelle.carbonneau@albertahealthservices.ca
780-492-9991

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion